PCSK9 and familial hyperaldosteronism: In recent years, combined treatment with statins and other lipid-lowering drugs has been a good therapeutic strategy to further reduce LDL-C levels for patients with FH [40]; the monoclonal antibody against PCSK9 is an innovative lipid-lowering drug.